UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib

Clinical pharmacokinetics, 2020-07, Vol.59 (7), p.849-856

2020

Volltextzugriff (PDF)

Protective role of melatonin in breast cancer: what we can learn from women with blindness

Cancer causes & control, 2022-01, Vol.33 (1), p.1-13

2022

Volltextzugriff (PDF)

Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis

Clinical infectious diseases, 2008-11, Vol.47 (9), p.1176-1184

2008

Volltextzugriff (PDF)

New Data on the Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma

European journal of breast health, 2021-10, Vol.17 (4), p.302-307

2021

Volltextzugriff (PDF)

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

Leukemia, 2022-11, Vol.36 (11), p.2739-2742

2022

Volltextzugriff (PDF)

Innovative approach to lymphadenectomy in breast sarcoma

Bulletin du cancer, 2022-10, Vol.109 (10), p.1017-1028

2022

Volltextzugriff (PDF)

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera

International journal of infectious diseases, 2019-03, Vol.80, p.134-136

2019

Volltextzugriff (PDF)

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

Experimental hematology, 2018-11, Vol.67, p.41-48

2018

Volltextzugriff (PDF)

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations

British journal of haematology, 2022-08, Vol.198 (3), p.535-544

2022

Volltextzugriff (PDF)

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Leukemia research, 2023-07, Vol.130, p.107308-107308, Article 107308

2023

Volltextzugriff (PDF)

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice

EJHaem, 2023-08, Vol.4 (3), p.779-791

2023

Volltextzugriff (PDF)

Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

British journal of haematology, 2012-07, Vol.158 (2), p.232-237

2012

Volltextzugriff (PDF)

Maladies de l’hémoglobine et thromboses artérielles/veineuses

Journal de médecine vasculaire, 2022-03, Vol.47, p.S19-S19

Amé, Shanti

2022

Volltextzugriff (PDF)

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

Oncology, 2015-01, Vol.88 (1), p.1-8

2015

Volltextzugriff (PDF)

Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients

Journal of clinical oncology, 2002-04, Vol.20 (7), p.1898-1906

2002

Volltextzugriff (PDF)

Prospective evaluation of the effect of deferasirox on hematologic response in transfusion‐dependent patients with low‐risk MDS and iron overload

European journal of haematology, 2018-08, Vol.101 (2), p.165-173

2018

Volltextzugriff (PDF)

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS

Leukemia research, 2011-11, Vol.35 (11), p.1530-1533

2011

Volltextzugriff (PDF)

Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

Annals of hematology, 2012-01, Vol.91 (1), p.39-46

2012

Volltextzugriff (PDF)

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

Oncotarget, 2016-06, Vol.7 (23), p.35293-35301

2016

Volltextzugriff (PDF)

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes

Haematologica (Roma), 2019-03, Vol.104 (3), p.497-504

2019

Volltextzugriff (PDF)

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM)

Blood, 2010-11, Vol.116 (21), p.3378-3378

2010

Volltextzugriff (PDF)

Can combination salvage therapy for invasive aspergillosis improve patient outcome?

Nature clinical practice. Oncology, 2005-04, Vol.2 (4), p.186-187

2005

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(91)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib

Protective role of melatonin in breast cancer: what we can learn from women with blindness

Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis

New Data on the Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

Innovative approach to lymphadenectomy in breast sarcoma

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice

Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

Maladies de l’hémoglobine et thromboses artérielles/veineuses

Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies

Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients

Prospective evaluation of the effect of deferasirox on hematologic response in transfusion‐dependent patients with low‐risk MDS and iron overload

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS

Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM)

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study

Can combination salvage therapy for invasive aspergillosis improve patient outcome?

Suchergebnisse filtern